Conference Proceedings

PHASE 1 STUDY OF AMG 160, A HALF-LIFE EXTENDED BITE (R) (BISPECIFIC T-CELL ENGAGER) THERAPY TARGETING PROSTATE-SPECIFIC MEMBRANE ANTIGEN, IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

Tanya Dorff, Matthew Rettig, Jean-Pascal Machiels, Martijn Lolkema, Karen Autio, Richard Greil, Sylvie Rottey, Nabil Adra, Mark Salvati, Shirley Poon, Daniel Tan, Gabor Jurida, Hosein Kouros-Mehr, Karim Fizazi, Ben Tran, Lisa Horvath

JOURNAL FOR IMMUNOTHERAPY OF CANCER | BMJ PUBLISHING GROUP | Published : 2020

Abstract

BackgroundProstate-specific membrane antigen (PSMA) is a clinically validated target for metastatic castration-resistant prostate cancer (mCRPC). AMG 160 BiTE® immuno-oncology therapy redirects T cells to cancer cells by binding to PSMA on cancer cells and CD3 on T cells, leading to T-cell activation, tumor-cell killing, and T-cell expansion. As the BiTE mode of action leads to an upregulation of immune checkpoints, combining AMG 160 with a PD-1 inhibitor may lead to sustained T cell–dependent killing of tumor cells. Cytokine release syndrome (CRS) is a first-dose effect induced by BiTE molecule-mediated T-cell activation. An approach to mitigate CRS is prophylaxis with an anti-inflammatory ..

View full abstract